{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=7", "query": { "intervention": "Treatment of physician's choice", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 158, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+of+physician%27s+choice&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:53:00.932Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Anti-PD-L1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Anti-PD1 Monoclonal Antibody", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Monitoring", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surveillance", "type": "BEHAVIORAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 535, "start_date": "2026-04-08", "completion_date": "2028-10-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 13, "location_summary": "Goodyear, Arizona • Corona, California • Duarte, California + 10 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288034" }, { "nct_id": "NCT05826964", "title": "Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "ER-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "AI+CDK4/6i", "type": "DRUG" }, { "name": "SERD+CDK4/6i", "type": "DRUG" }, { "name": "mTOR inhibitor + AI", "type": "DRUG" }, { "name": "mTOR inhibitor + SERD", "type": "DRUG" }, { "name": "mTOR inhibitor + Selective estrogen receptor modulator", "type": "DRUG" }, { "name": "PI3K inhibitor + SERD", "type": "DRUG" }, { "name": "PI3K inhibitor + AI", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Oral SERD", "type": "DRUG" }, { "name": "PARPi", "type": "DRUG" }, { "name": "AKT inhibitor", "type": "DRUG" }, { "name": "Step 3 Arm 2", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-06-12", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826964" }, { "nct_id": "NCT02915744", "title": "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastasis", "Breast Cancer" ], "interventions": [ { "name": "NKTR-102", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2016-11", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 19, "location_summary": "Tucson, Arizona • Orange, California • San Francisco, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915744" }, { "nct_id": "NCT07001748", "title": "Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Standard of Care Chemotherapy", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diagnostic Laparoscopy", "type": "PROCEDURE" }, { "name": "Intraperitoneal Port Placement", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Intraperitoneal Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2025-10-24", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 78, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 64 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07001748" }, { "nct_id": "NCT07287150", "title": "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2026-03-11", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Iowa City, Iowa + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "The Bronx", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287150" }, { "nct_id": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2011-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-10-12", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 59, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Hayward", "state": "California" }, { "city": "Highland", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01419197" }, { "nct_id": "NCT01857817", "title": "Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "VT-122", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vicus Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 35, "start_date": "2013-06", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 16, "location_summary": "Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Parker", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01857817" }, { "nct_id": "NCT04008797", "title": "A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Neoplasms", "Neoplasms", "Carcinoma, Hepatocellular", "Liver Neoplasms", "Colorectal Neoplasms" ], "interventions": [ { "name": "E7386", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 301, "start_date": "2019-07-11", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 22 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008797" }, { "nct_id": "NCT02625623", "title": "Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma", "Gastric Cancer Third Line" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Best Supportive Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2015-12-28", "completion_date": "2019-11-13", "has_results": true, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 28, "location_summary": "Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pueblo", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02625623" }, { "nct_id": "NCT05255107", "title": "Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Keratitis", "Corneal Ulcer" ], "interventions": [ { "name": "Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution", "type": "COMBINATION_PRODUCT" }, { "name": "Standard of Care Therapy + Sham CXL + Artificial Tears", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "Peschke GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 468, "start_date": "2022-03-14", "completion_date": "2024-02-24", "has_results": false, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-10-14T04:53:00.932Z", "location_count": 12, "location_summary": "Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255107" } ] }